Key Points
- CFO Dominic Piscitelli sold 13,400 Oric Pharmaceuticals shares at an average price of $13.53, generating $181,302. The Rule 10b5-1 transaction reduced his direct ownership by 16.1% to 69,828 shares.
- Oric shares opened at $13.37, with a market capitalization of approximately $1.39 billion and a 12-month trading range of $7.23 to $14.93. The company recently reported quarterly EPS of negative $0.38, missing the consensus estimate of negative $0.36.
- Analyst sentiment remains generally positive, with a “Moderate Buy” consensus and an average price target of $20.18; 13 analysts rate the stock Buy, compared with one Hold and one Sell.
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 13,400 shares of Oric Pharmaceuticals stock in a transaction on Monday, September 28th. The stock was sold at an average price of $13.53, for a total transaction of $181,302.00. Following the transaction, the chief financial officer directly owned 69,828 shares of the company's stock, valued at $944,772.84. The trade was a 16.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dominic Piscitelli also recently made the following trade(s):
- On Thursday, September 24th, Dominic Piscitelli sold 600 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.50, for a total transaction of $8,100.00.
- On Wednesday, August 26th, Dominic Piscitelli sold 77,000 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.69, for a total transaction of $1,054,130.00.
Oric Pharmaceuticals Trading Up 0.8%
Oric Pharmaceuticals stock opened at $13.37 on Wednesday. The firm has a 50-day moving average price of $12.89 and a 200-day moving average price of $10.85. The firm has a market capitalization of $1.39 billion, a PE ratio of -9.90 and a beta of 1.00. Oric Pharmaceuticals, Inc. has a 12-month low of $7.23 and a 12-month high of $14.93.
Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.02). As a group, sell-side analysts predict that Oric Pharmaceuticals, Inc. will post -1.53 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on ORIC. BTIG Research started coverage on Oric Pharmaceuticals in a research report on Wednesday, September 23rd. They set a "buy" rating and a $26.00 target price for the company. HC Wainwright increased their price target on Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of Oric Pharmaceuticals in a research note on Friday, July 17th. Benchmark restated a "buy" rating on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Finally, Wall Street Zen raised Oric Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, July 25th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Oric Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $20.18.
View Our Latest Report on Oric Pharmaceuticals
Institutional Investors Weigh In On Oric Pharmaceuticals
Several large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in Oric Pharmaceuticals in the 2nd quarter worth about $73,904,000. Siren L.L.C. increased its position in shares of Oric Pharmaceuticals by 197.6% during the first quarter. Siren L.L.C. now owns 2,998,192 shares of the company's stock worth $37,987,000 after acquiring an additional 1,990,617 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Oric Pharmaceuticals by 19.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company's stock valued at $18,637,000 after acquiring an additional 244,060 shares in the last quarter. Algert Global LLC raised its stake in shares of Oric Pharmaceuticals by 791.3% during the second quarter. Algert Global LLC now owns 1,215,293 shares of the company's stock valued at $13,162,000 after acquiring an additional 1,078,943 shares in the last quarter. Finally, Braidwell LP boosted its holdings in shares of Oric Pharmaceuticals by 7.7% in the second quarter. Braidwell LP now owns 1,214,540 shares of the company's stock valued at $13,153,000 after purchasing an additional 86,500 shares during the period. 95.05% of the stock is owned by hedge funds and other institutional investors.
Oric Pharmaceuticals Company Profile
(
Get Free Report)
Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. The company seeks to address treatment resistance by targeting biological mechanisms that allow tumors to survive or evade existing therapies, with an emphasis on restoring or enhancing the effectiveness of anti-cancer treatment.
Oric's research and development portfolio has included small-molecule drug candidates aimed at targets such as CD73 and the polycomb repressive complex 2 (PRC2).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
